Schonfeld Strategic Advisors LLC Raises Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Schonfeld Strategic Advisors LLC raised its position in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 301.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,558,621 shares of the biopharmaceutical company's stock after buying an additional 5,676,021 shares during the quarter. Schonfeld Strategic Advisors LLC owned about 3.07% of Lexicon Pharmaceuticals worth $5,582,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in LXRX. RPO LLC bought a new position in Lexicon Pharmaceuticals during the fourth quarter worth $33,000. Renaissance Technologies LLC bought a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter valued at about $38,000. Arizona State Retirement System grew its stake in Lexicon Pharmaceuticals by 34.4% during the fourth quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company's stock worth $47,000 after purchasing an additional 16,136 shares during the period. Teacher Retirement System of Texas increased its stake in shares of Lexicon Pharmaceuticals by 60.3% in the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company's stock valued at $48,000 after acquiring an additional 24,615 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth about $66,000. 74.70% of the stock is currently owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Price Performance

Shares of Lexicon Pharmaceuticals stock traded down $0.06 during trading on Tuesday, hitting $0.66. The stock had a trading volume of 4,749,265 shares, compared to its average volume of 6,475,149. The firm has a market cap of $237.10 million, a price-to-earnings ratio of -0.87 and a beta of 1.07. Lexicon Pharmaceuticals, Inc. has a 12 month low of $0.28 and a 12 month high of $2.45. The business's 50-day moving average is $0.49 and its 200 day moving average is $0.78. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.11) by $0.02. The firm had revenue of $26.55 million during the quarter, compared to the consensus estimate of $6.48 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. As a group, sell-side analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on LXRX shares. HC Wainwright reissued a "buy" rating and set a $4.00 target price on shares of Lexicon Pharmaceuticals in a research report on Friday, March 28th. Needham & Company LLC reiterated a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Monday, March 3rd. StockNews.com began coverage on shares of Lexicon Pharmaceuticals in a research report on Monday, April 21st. They set a "sell" rating for the company. Leerink Partners reissued a "market perform" rating and issued a $1.00 price target (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, March 4th. Finally, Piper Sandler cut their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an "overweight" rating for the company in a report on Friday, March 7th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, Lexicon Pharmaceuticals has a consensus rating of "Hold" and a consensus target price of $3.67.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.